DERIVATIVES OF POLYENE MACROLIDE ANTIBIOTICS CONTAINING AN AMINO SUGAR MOIETY, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Abstract: Disclosed are novel derivatives of polyene macrolide antibiotics of the general formula wherein M is a polyene macrolide antibiotic moiety contain­ ing an amino sugar moiety, the amino group of which is substituted by X, wherein X is ---NH---NR₃R₄ (III), -R₅ or hydrogen, wherein A and B independently of each other are hydrogen or NR₃R₄ or one of A and B is hydrogen and the other is -NH--R-NR₃R₄; R₅ is an α-amino acyl group; n is 1 to 3, t is zero or 1, and when t is zero p is zero to 4 and when t is I p is zero; z is zero or I, and Y is hydrogen, alkyl, allyl, propargyl, benzyl or phenylpropar­ gyl, with the proviso that, when X is hydrogen, z must be I and Y allyl, propargyl, benzyl or phenylpropargyl; and the pharmaceutically acceptable acid addition salts thereof. The novel compounds may be prepared by methods known per se. Preferably the compounds are prepared by reaction of respective polyene macrolide antibiotic with a reactive derivative of a compound HOX wherein the amino group(s) is (are) protected. The compounds wherein X is hyd­ rogen and Y is allyl, propargyl, benzyl or phenylpropargyl can be prepared by reaction of the respective N-protected polyene macrolide antibiotic with a reactive derivative of propene, propyne, phenylpropyne or toluene. The compounds show antifungal activity and are useful in the treatment of fungal infections.

Description: Derivatives of polyene mac > -oliae antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them. This invention relates to derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them. It has been established that compounds of this invention show antifungal activity and are useful in the treatment of fungal infections. Polyene macrolide antibiotics containing an amino sugar moiety are known in the art. In general they are useful in the treatment of mycosis, benign prostatic hypertrophy and elevated blood cholesterol. 2\rnona such known polyene macrolides are amphotericin B, candicidin and nystatin which are used as anti-fungal agents. The most commonly known and used agent is amphotericin B in the form of its sodium desoxycholate complex, which is sold under the registered trademark FUNGIZONE. Lack of water solubility, poor stability, and toxic properties have hindered other polyene macrolides achieving an important place in therapy. Attempts have been made to improve the usefulness of amphotericin B. Straight chain alkyl esters of amphotericin B and a number of other polyene antibiotics have been reported. The reports indicate that these esters and their salts generally have reduced toxicity compared with the parent polyene antibiotics, but at the same time they also have reduced activity. N-Acyl derivatives of these compounds have also been prepared and, again, although they have been found to be less toxic than their parent polyene antibiotics, they have also been found to be less potent. N-Glycosyl derivatives of certain polyene antibiotics have also been reported and these appear to be equipotent or more potent than their parents and about as toxic. According to the prior art it was not possible so far, to produce a less toxic but potent systemic anti-fungal agent. The novel compounds of this invention are the polyene macrolide antibiotic derivatives of the general formula EMI2.1 wherein M is a polyene macrolide antibiotic moiety containing an amino sugar moiety, the amino group of which is substituted by X, wherein X is EMI2.2 wherein A and B independently of each other are hydrogen or NR3R4 or one of A and B is hydrogen and the other is EMI3.1 R is a saturated hydrocarbon group having 1 to 10 carbon atoms; R1 and R2 independently of each other are hydrogen or a straight chain alkyl group having 1 to 3 carbon atoms or one of R1 and R2 is hydrogen and the other a straight chain alkyl group having 1 to 3 carbon atoms substituted by an NH2 group; R and independently of each other are hydrogen or a straight chain alkyl group containing 1 to 3 carbon atoms; R5 is histidyl, tyrosyl, tryptophyl, arginyl, phenylalanyl or prolyl or an EMI3.2 derivative of histidyl, tyrosyl, tryptophyl, phenylalanyl or prolyl; m is .1 or 2; n is 1 to 3, t is zero or 1, and when t is zero p is zero to 4 and when t is 1 p is zero; with the proviso that not more than one hetero atom is attached to the same carbon atom in any one of R, R1 and B2 and that in those compounds containing more than one R-group, these R-groups may be of the same or different chain length; z is zero or 1, and Y is hydrogen, an alkyl group containing 1 to 10 carbon atoms, allyl, propargyl, benzyl or phenylpropargyl, with the proviso that, when X is hydrogen, z must be 1 and Y must be allyl, propargyl, benzyl or phenylpropargyl; and the pharmaceutically acceptable acid addition salts of all the foregoing compounds. Preferably these derivatives are derived from a polyene macrolide antibiotic of the general formula EMI4.1 wherein z is zero or 1, which is amphotericin B, ascocin, aureofacin, aureofungin A, aereofungin B, candicidin, candidin, eurotin A, flavomycin, fulvomicin A, fulvomicin B, fulvomicin C, fungimycin, hamycin A, leucensomycin, levorin, mycoheptin, nystatin A, partricin, pimaricin , polyfungin, rimocidin, trichomycin A, vacidin A, DJ-400 B1, DJ-400 B2, 67-121A, 67-121B, 67-121C, PA 150, PA 616, or 2814 H, of which pimaricin and 67-121C and especially amphotericin B are most preferred.-The amino sugar moiety generally is mycosamine or perosamine Some of the polyene macrolide antibiotics contain aromatic moieties on the macrolide ring and these aromaticr1ngsWmay also contain an amine group; however, under thetreaction conditions of this invention, these amine groups are not involved. As stated before R is a saturated hydrocarbon having 1 to 10 carbon atoms, said hydrocarbon may be a straight or branched chain alkylene group, such as for example methylene, ethylene, n-propylene, isopropylene,n-butylene, isobutylene, tert.-butylene, B-methylpropylene, pentylene, hexylene, heptylene, octylene, nonylene, decylene and the like. Preferably R is a straight chain alkylene group especially a group containing 1 to 5 carbon atoms. Those derivatives are preferred wherein X is EMI5.1 wherein n is 1 or preferably 2 and R, R1 and R2 are as defined above. Preferred are those derivatives wherein R1, R2, R3 and Rare hydrogen, and, provided that the compound contains two NH2 groups, one of the amino groups is terminal. As is apparent from the above,substituent X (formula I) may consist of one, two or three aminoacyl groups, preferably alanyl, glycyl, histidyl, tryptophyl, isoleucyl, leucyl, lysyl, norvalyl, ornithyl, phenylalanyl, prolyl, seryl, tyrosyl or valyl. X may contain identical or different amino acyl groups, so that X is glycyl-glycyl, glycyl-lysyl, leucyl-leucyl, alanyl-lysyl, histidyllysyl, and the like. Preferably X is lysyl or ornithyl. In those instances where the group X has one or more chiral centers, the diastereomeric derivatives of formula I may be used separately or in admixture. For example, the nature of the synthesis may result in formation of a N-[D]-lysyl, a N-[L]-lysyl, or a N-FD,Li-lysyl amphotericin B, the latter being an equal mixture of the first two. Derivatives of polyene macrolide antibiotics containing a carboxylic acid function (i.e. compounds of formula I wherein z is 1) are preferred in the form of their esters. Derivatives are preferred wherein Y is an alkyl group containing I to 4 carbon atoms, especially those wherein Y is methyl. Also the novel esters of formula I, wherein X is hydrogen, z is one and Y is allyl, propargyl, phenylpropargyl qr beflzyl are of interest. The pharmaceuticallyJaccgeptable acid addition salts of this invention can be derived from inorganic acids, such as for example hydrochloric, sulfuric, and phosphoric acid, or from organic acids such as for example formic, maleic and tartaric acid. The physical embodiments of the salts are characterized by being colorless to yellow/orange solids (dependent on the degree of unsaturation of the polyene) which are soluble in water, sparingly soluble in most polar organic solvents and insoluble in most non-polar organic solvents. Of the compounds of this invention the following are of special interest: N-D-lysyl amphotericin B methyl ester, N-D-ornithyl amphotericin B methyl ester, N-D-lysyl pimaricin methyl ester, N-glycyl 67-121C, N-glycyl amphotericin B methyl ester, N-D-2,4-diaminobutyryl amphotericin B methyl ester, N--alanyl amphotericin B methyl ester, N-(aminoethylglycyl) amphotericin B, N-(aminoethylglycyl) amphotericin B methyl ester, N-D-lysyl amphotericin B, N-L-lysyl amphotericin B, N-L-lysyl amphotericin B methyl ester, N-L-ornithyl amphotericin B methyl ester, N-D-ornithyl amphotericin B propargyl ester, N-(2-aminoethoxycarbonyl) amphotericin B methyl ester, N-L-histidyl amphotericin B methyl ester, amphotericin B allyl ester, amphotericin B propargyl ester, amphotericin B (3-phenyl-2-propynyl) ester, N-D-lysyl amphotericin B propargyl ester, N-histidyl-lysyl amphotericin B methyl ester, N-Dornithyl-amphotericin B, N-L-orithyl amphotericin 9, and the pharmaceutically acceptable acid addition salts, especially hydrochloride salts, thereof. The compounds of this invention are useful in the treatment of mycosis, benign prostatic hypertrophy and elevated blood cholesterol, as the known polyene macrolide antibiotics. The compounds of this invention are especially useful as anti-fungal agents. Surprisingly, in tests compounds of this invention have shown to be less toxic and more active than the respective known polyene macrolide antibiotics. The compounds of this invention thus can be used to effectively combat fungus infections of the following species: Histoplasma capsulatum, Coccidiodes immitis, Candida spp., Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans , Sporotrichum schenckii, Mucor mucedo, Aspergillus fumigatusss Trichophyton spp., Microsporum spp. and Epldermophyton. Additionally, the compounds have been found to be active fungicidally rather than fungistatically- The properties of the compounds of this invention can be illustrated by the following test results: Table 1 In vitro Activity Organisms Average MIC's (mcg/ml, 48hrs.)S.D.B. pH 5.8 Compound: A B C D 64 strains 0.02 0.03 0.04 0.08 Candida albicans 13 strains 0.02 0.02 0.05 0.10 non-albicans yeasts 2 filamentous 0.04 0.10 0.11 0.23 fungi Table 2 Effective Dose (Ed, mg/kg) Needed to Curea Mice Infected with Verious Strains of Candida Albicans and LD50-I.V. Mice (mg/kg) ED[mg/kg] LD50[mg/kg] Compound C.albicans Strains Wisconsin C-1-7 C-60 Sparks D | 0.7 3 1 1.2 4 C 20 100 A 0.7 3 1.5 2.6 35-40 B 0.7 3 1,5 2.6 35-40 Reduce counts to below 105/mouse kidneys. Compound A: N-D-lysyl amphotericin B methyl ester dihydrochloride. Compound B: N-D-ornithyl amphotericin B methyl ester dihydrochloride. Compound C: amphotericin B methyl ester. Compound D: fungizone (=amphotericin B as the sodium desoxycholate complex). In general, the compounds of this invention and their pharmaceutically acceptable acid addition salts may be administered orally, e.g. compounded-in the form of tablets, capsules, elixirs or the like, or they may be applied topically, e.g. in the form of ointments, lotions, creams or gels. Preferentially, they may be administered parenterally via intramuscular, intravenous, subcutaneous, intralesional and intrasternal injection. The injectable solution will usually be administered at from about 1 mg to 5 mgs of compound per kilogram of body weight per day. Pharmaceutical carriers useful in the preparation of the foregoing formulations will include, for example, such substances as water, oils, fats, waxes, polyesters, alcohols, polyols and the like. The present invention includes within its scope the method for treating fungal infections which comprises administering to a mammal infected with a susceptible fungus a non-toxic fungicidally effective amount of a compound of this invention. Also included within the inventive concept are pharmaceutical compositions comprising a non-toxic, fungicidally effective amount of a compound of this invention together with a nontoxic, pharmaceutically acceptable carrier. The compounds of this invention can be prepared according to known methods, especially according to methods known from peptide synthesis. In these methods the polyene macrolide antibiotics containing an aminosugr moiety are used as starting material, especially amphotericin B, ascocin, aureofacin, aureofungin A, aureofungin B, candicidin, candidin, eurotin A, flavomycin, fulvomicin A, fulvomicin B, fulvomicin C, fungimycin, hamycin A, leucensomycin, levorin, mycoheptin, nystatin A, partricin, pimaricin, polyfungin, rimocidin, trichomycin A, vacidin A, DJ-400 B1, DJ-400 B2, 67-121A, 67-121B, 67-121C, PA 150, PA 616 and 2814H. The polyene macrolides are highly insoluble compounds so that when they are reacted with other compounds, various polar organic solvents must be used as, for example, dimethylformamide, dimethylsulfoxide, and hexamethylphosphoric- triamide. In reactions wherein acylation of the polyene's hydroxyl group(s) has to be prevented a small amount of methanol to any of the polar solvents is usually added. A. For the preparation of derivatives of polyene macrolide antibiotics of the general formula EMI12.1 wherein M is a polyene macrolide antibiotic moiety containing an amino sugar moiety, the amino group of which is substituted by X, wherein X is EMI13.1 -R5, wherein A and B independently of each other are hydrogen or NR3R4 or one of A and B is hydrogen and the other is EMI13.2 R is a saturated hydrocarbon group having 1 to 10 carbon atoms; R1 and R2 independently of each other are hydrogen or a straight chain alkyl group having 1 to 3 carbon atoms or one of R1 and B2 is hydrogen and the other a straight chain alkyl group having 1 to 3 carbon atoms substituted by an NH2 group; B and 3 independently of each other are hydrogen or a straight chain alk-yl--group containing 1 to 3 carbon atoms; B is histidyl, tyrosyl, tryptophyl, arginyl, phenylalanyl or prolyl or an (&alpha;)-N-[(NH2)m EMI13.3 C0)-derivative of histidyl, tyrosyl, tryptophyl, phenylalanyl or prolyl; m is 1 or 2; n is 1 to 3, t is zero or 1, and when t is zero p is zero to 4 and when t is 1 p is zero; with the proviso that not more than one hetero atom is attached to the same carbon atom in any-one of R, R1 and R2 and that in those compounds containing more than one R-group, these R-groups may be of the same or different chain length; z is zero or 1, and Y is hydrogen, an alkyl group containing 1 to 10 carbon atoms, allyl, propargyl, benzyl or phenylpropargyl, with the proviso that, when X is hydrogen, z must be 1 and Y allyl, propargyl, benzyl or phenylpropargyl; a polyene macrolide antibiotic of the general formula EMI14.1 wherein M, Y and z are as defined above, is reacted with a reactive derivative of a compound of the general formula HOX'(VII), wherein X' is defined as group X above with the exception that the amino groups contained therein are protected. This reaction is followed by the removal of the protecting group(s) and, if desired, esterification of compounds containing a carboxylgroup. For the preparation of compounds containing an esterified carboxylgroup it is preferred, however, to carry out the said esterification before removing the protecting group(s). The process may be outlined by the following reaction scheme: EMI15.1 In the formulae of this reaction scheme M, Y, z and X' are as defined above and Z is an eliminable group, such as for example N-hydroxysuccinimidyl, N-hydroxyphthalimidyl or an acyl imidazolyl. Preferably Z is Nhydroxysuccinimidyl. The amino groups contained in compound ZX' are protected by easily removable groups, such as for example triflucro acetyl, 2,2, 2-trichloroethoxycarbonyl and fluorenernethoxy- carbonyl, the latter group being preferred. The reaction of the compounds of formula VI and VIII is carried out in a polar oranic solvent such as dimethylformamide, dimethylsulfoxide, hexamethylphosphorie triamide or mixtures of these solvents. In reactions wherein acylation of possible hydroxyl group(s) of the polyene antibiotic has to be prevented a small amount of methanol can be added. Several other means can be used to support this reaction, such as performing the reaction under nitrogen and/or addition of triethylamine. The compound ZX' can be prepared by known methods. For the preparation of compounds of formula I wherein X is the group EMI16.1 wherein t is one, p is zero and B, R1, R2 and n are as defined above, ZX' (VIII) can be prepared by reacting an appropriate N-protected aminoalkanol with phosgene and then with preferably N-hydroxysuccinimide, For the preparation of all other compounds of formula I ZX' can be prepared by reacting the appropriate Nprotected amino acid with preferably N-hydroxysuccinimide and dicyclohexylcarbodiimide. The reaction conditions under which the protecting groups of the amino groups are removed in this process are known in the art and depend on the kind of protecting group. Compounds of formula I and IX containing a free carboxy group, (wherein z is one and Y is hydrogen) can be esterified by reaction with a reactive derivative of the appropriate hydrocarbon. The compounds of formula I, having a free carboxyl group and at least one free amino group, can be esterified for example by reaction with the appropriate diazo derivative of the hydrocarbon such as diazomethane, diazoethane, diazopropane or diazobutane (e.g. as described in U.S. Patent No. 3.936.526 and 4.038.382). The compounds of formula IX, which are compounds containing one or more protected amino groups can be reacted with alkylating agents such as for example methyl iodide, methyltosylate, ethyliodide, or with allyliodide, propargyl bromide methyl sulfate and phenylpropargyl bromide. In this alkylation reaction it is preferred to use compounds of formula IX wherein the amino group(s) is(are) protected by fluorenemethyloxycarbonyl. B. For the preparation of a derivative of a polyene macrolide antibiotic of the general formula EMI17.1 wherein M is a polyeneemacrolide antibiotic moiety containing an amino sugar moiety, the amino group of which is substituted by X, wherein X is -CO-CH2-NHR1 (X), wherein R1 is hydrogen, or a straight chain alykl group having 1 to 3 carbon atoms which may be substituted by an NH2 group; z is zero or 1, and Y is hydrogen, an alkyl group containing 1 to 10 carbon atoms, allyl, propargyl, benzyl or phenylpropargyl, a N-iodoacetyl derivative of the polyene macrolide antibiotic is reacted with an amine of the general formula H2NR1 (XI), wherein R1 is as defined above and, if desired,esterified, provided the macrolide contains a carboxy group. The reaction is carried out in a polar solvent such as for example dimethylformamide, dimethylsulfoxide and hexamethylphosphorictriamide. Methanol may be added to the solvent. By this process derivatives such as for example the N-glycyl, N-methylglycyl and N-aminoethylglycyl derivatives of the polyene macrolide antibiotics can be prepared. The so obtained compounds can be esterified as described in process A. The N-iodoacetyl derivatives of the polyene macrolide antibiotics can be prepared by reacting the relevant macrolide with iodoacetic anhydride in a polar organic solvent. C. For the preparation of novel derivatives of polyene macrolide antibiotics of the general formula EMI18.1 wherein X is hydrogen z 5 one, Y is allyl, propargyl, benzyl or phenylpropargyl and M is as defined above an appropriate polyene macrolide antibiotic which contains a carboxylgroup is esterified. The preferred process for the preparation of these compounds is a novel process, which is also applicable to the preparation of alkylesters of polyene macrolide antibiotics containing a carboxylgroup. (These alkyl esters are known in the art and are not covered by the product aspect of this invention). By this novel process it is possible to prepare the esters wherein Y is allyl, propargyl, benzyl or phenylpropargyl, which can not be prepared by theprocesses known in the art. In this process the carboxylic acid salt of the polyene macrolide antibiotic, wherein the amino group of the amino sugar moiety has been protected by the treatment with an excess of an aromatic aldehyde, is reacted with the reactive derivative of the relevant hydrocarbon. Preferably the reaction is carried out in a polar solvent such as for example hexamethylphosphorictriamide, dimethylsulfoxide or dimethylformamide wherein the macrolide is soluble. As soon as the reaction is finished the protecting group is removed and the desired ester of the polyene macrolide antibiotic is isolated. Aromatic aldehydes suitable for the above reaction are for example paramethoxybenzaldehyde, paranitrobenzaldehyde, salicylaldehyde and benzaldehyde. As reactive derivatives of the relevant hydrocarbons (alkanes, propene, propyne, phenylpropyne and toluene) can be used, their bromides, iodides and the like, bromides being preferred. The reactive derivatives may be exemplified by methyl iodide, ethyl iodide, allyl iodide, propargyl bromide methyl sulfate and phenylpropargyl bromide. The so obtained products may be subjected to an after treatment such as, transformation into the pharmaceutically acceptable acid addition salt. The salts are made according to known procedures such as by neutralizing the free base with the appropriate acid, usually to about pH 5. The acid addition salts may be mono or di- in nature depending on the number of free amine groups in the compound, the amount of acid used and whether or not the carboxy group possibly contained in the base is esterified. The above processes are exemplified by the following Examples. Example 1 N-(2-Aminoethoxycarbonyl)Amphotericin B A. N-Trifluoroacetyl-Ethanolamine Ethanolamine (12 g) is dissolved in methanol (50 ml) ano S-ethylthiotrifluoroacetate (35 g ) is added dropwise. The reaction is permitted to stand overnight irrigated with a stream of argon to remove ethanethiol. Tbe excess solvent is removed in vacuo to leave the title product. B. 2-N-Trifluoroacetylaminoethoxycarbonyloxy Succinimide N-Trifluoroacetyl-ethanolamine (7.8 g) in dichloromethane (100 ml) is treated with phosgene (15 g) in dichloromethane (120 ml). Triethylamine (6 ml) is added dropwise with stirring. After four hours at room temperature excess phosgene is removed by the rapid passage of nitrogen and the solution is filtered and the solvent removed in vacuo, The residue is dissolved in dichloromethane (100 ml) and N-hydroxysuccinimide (5.8 g) and pyYldïne (12 g) are added. After 18 hours the solvent is removed under vacuum to provide the named compound as a residue which is used without further purif¯eation. C. N-(2-N'-Trifluoroacetylaminoethoxycarbonyl) Amphotericin B Amphotericin B (2 g) in 27.5 ml of a 9:1 dimethylsulfoxide: methanol mixture is treated with 2-N-trifluoro- acetylaminoethoxycarbonyloxysuccinimide (3.9 g) dissolved in a minimum amount of tetrahydrofuran, added in portions over 7.5 hours. Triethylamine (327 mg) is added and the mixture is stirred for 2,5 hours, The mixture is then diluted with 25 ml of methanol and added dropwise to 600 ml of ether, Filtration of the yellow precipitate, washing with ether and drying gives the named compound: # max (KBr) 1715 cm-1; # max. (20% aqueous tetrahydrofuran), 348 nm (EÚ1%=263), 367 nm (EÚ1%=563), 386 nm (EÚ1%=946), 410 nm (EÚ1%=1056). D. N-(2-Aminoethoxycarbonyl)Amphotericin B N-(2-N'-trifluoroacetylaminoethoxycarbonyl)amphotericin B (1.985 g) in 60 ml of a 1:1 dimethylformamide: concentrated ammonium hydroxide mixture is stirred 9.5 hours with monitoring by thin layer chromatography (2:2:1 chloroform:methanol:water, lower phase). Dilution with 60 ml methanol and dropwise addition to excess ether yields a yellow precipitate which is filtered, washed with ether and dried. The precipitate is dissolved in 10 ml dimethylsulfoxide and chromatographed on 250 g SiO2 eluted with the lower phase of a 2:2;1 chloroform: methanol:water mixture, to obtain the title compound: 26+ 213.6 (DMSO); #max (20% aqueous tetrahydrofuran) 348 nm (EÚ1%=310), 367 nm (E11=680), 386 nm (E1%=1140), 410 nm (EÚ1%=1270). Example 2 N-Glycyl Amphotericin B Methyl Ester Hydrochloride A. N-Trifluoroacetylglycyloxy Succinimide N-Trifluoroacetylglycine (684 mg) and N-hydroxysuccinimide (480 mg) in 5 ml od dry CH2Cl2 at 50 C are treated with a solution of 915 mg dicyclohexylcarbodiimide (4,43 mmol) in 5 ml of CH2C12. The mixture is stirred at room temperature overnight, is then filtered and evaporated to produce the named compound which can be used in subsequent reactions without further purification. B. N-(N'-trifluoroacetylglycyl)amphotericin B Amphotericin B (500 mg) in 5.5 ml 9:1 dimethylsulfoxide: methanol with 246 mg of the product of step A is stirred at 250C for three hours, The mixture is diluted with 5 ml methanol and added dropwise to 100?iiilrether. The yellow precipitate is filtered, washed with ether and dried to give the named compound; # max (KBr) 1710, 1680 cm-1. C. N-Glycyl Amphotericin B N-(N'-trifluoroacetyIglycyl)amphotericin B (372 mg) in 13 ml 40% concentrated solution of ammonium hydroxide in dimethylformamide is stirred at.room temperature with careful monitoring by thin layer chromatography (SiO2 eluted with the lower phase of a 2:2:1 chloroform: methanol:water mixture). After 5 hours the mixture is reduced to half volume in vacuo, diluted with an equal volume of methanol and added dropwise to excess ether. The resulting yellow precipitate is filtered, triturated twice with ethanol and once with ether and dried to produce the. named compound. D. N-Glycyl Amphotericin B Methyl Ester A solution of N-glycyl amphotericin B (75 mg) in 2 ml dimethylsulfoxide is treated with ethereal diazomethane. After evolution of nitrogen has ceased, the reaction is judged complete on the basis of thin layer chromatography (SiO2 eluted with the lower phase of either a 2:2:1 chloroform:methanol:water or 1:1:1 chloroform:methanol: concentrated ammonium hydroxide mixture). The mixture is diluted with 2 ml methanol and added dropwise to excess ether. The resulting yellow precipitate is filtered, washed with ether and dried to produce the named compound: 9 max (KBr): 1710, 1660 -1 E. N-Glycyl Amphotericin B Methyl Ester Hydrochloride To N-glycyl amphotericin B methyl ester dissolved in aqueous tetrahydrofuran (1:1) is added 0.1 N hydrochloric acid until a pH of 5 is reached. The solution is filtered through a 0.45 micropore filter. The filtrate is lyophilized to yield the title compound: [&alpha;]26D-580 (H20); X max (20% aqueous tetrahydrofuran) 367 nm (EÚ1%=800), 387 nm (EÚ1%=1280), 411 nm (EÚ1%=1430). Example 3 N-D,L-Lysyl Amphotericin B Methyl Ester A. N-(N',N"-Bis-Trifluoroacetyl-L-Lysyl)amphotericin B N,N'-bis-trifluoroacetyl-L-lysine is treated with N-hydroxysuccinimide according to Example 2A to obtain N,N'-bis trifluoroacetyl-L-lysyloxy succinimide; [&alpha;]26D-31.4 (EtOH); #max (KBr) 1810, 1790, 1740, 1700 cm This product (473 mg) is added under nitrogen to amphotericin B (500 mg) in 5 ml of a 9:1 dimethylsulfoxide:methanol mixture. After 3.5 hours, 6 ml of methanol is added and the mixture is added dropwise to excess ether. A fine, yellow precipitate is allowed to settle with cooling overnight. Filtration, washing with ether and drying gives the named compound: [&alpha;]26D+263.2 (dimethylsulfoxide); # max (KBr) 1710 cm-1 B. - N-D,L-Lysyl Amphotericin B N-(N',N"-bis-trifluoroacetyl-L-lysyl)amphotericin B (418 mg) in 30 ml of a 1:1 concentrated ammonium hydroxide: methanol mixture is stirred with careful monitoring by thin layer chromatography, (SiO2 eluted with the lower phase of a 2:2:1 chloroform:methanol:water mixture). After 11.5 hours the mixture is added dropwise to excess ether. The yellow precipitate is filtered and washed successively with ethanol and ether, providing the named compound: [&alpha;]26D+ 293.40 (DMSO); # max (KBr) 3400, 1710-1630 cm-1; # max (20% aqueous tetrahydrofuran), 348 nm (E1% =340), 367 nm (EÚ1%=750), 386 nm (E1%=1280, and 410 nm 1 =1430). C. N-D,L-Lysyl Amphotericin B Methyl Ester A solution of N-D,L-lysyl amphotericin B (319 mg) in 5 ml of dimethylsulfoxide under nitrogen is treated with an excess of etheral diazomethane, When a complete reaction is indicated by thin layer chromatography (SiO2 eluted with the lower phase of a 1:1:1 chloroform:methanol: concentrated ammonium hydroxide mixture), the excess diazomethane is removed by a nitrogen stream and the resulting solution is diluted with 5 ml of methanol.Dropwise addition to excess ether yields a yellow precipitate which is filtered, washed with ether and dried to yield N-D,L-lysyl amphotericin B methyl ester; # max (KBr) 1720 cm-1; [&alpha;]26D+290.9 (DMSO); # max (20% aqueous tetrahydrofuran) 348 rim (EÚ1%= 340), 367 nm (EÚ1%=770), 386 nm (E11=l300), 410 nm (E11%= 1450). Example 4 N-L-Lysyl Amphotericin B Methyl Ester A. N,N'-Bis-Trichloroethoxycarbonyl-l-Lysyloxy Succinimide To L-lysine (2.92 g) in 60 ml of methanol is added trichloroethyl-N-hydroxysuccinimidyl carbonate (14.55 g). The mixture is stirred overnight at room temperature, then treated with 2.5 ml concentrated ammonium hydroxide and stirred another 0.5 hour. The solvent is evaporated in vacuo and the residue is extracted with water and ethyl acetate. The organic layer is extracted successively with cold 5% HC1, water and brine solution, and then is dried over MgSO4. Filtration and evaporation produces N,N1- bis-trichloroethoxycarbonyl-l-lysine as a glass. An analytical sample is prepared by two precipitations from [&alpha;]26D-7. chloroform/hexane; [&alpha;]D26 7.6 (EtoH); #max (KBr) 1720 cm-1 In a manner similar to Example 2A,utilizing anhydrous ethyl acetate as the solvent, N,N'-bis-trichloroethoxycarbonyl-L-lysine is reacted with N-hydroxy succinimide to obtain the above named compound; [&alpha;]26D-19.6 (EtOH); 9 max (KBr) 1820, 1785, 1715 cm B. N-(N"-Bis-Trichloroethoxycarbonyl-L-Lysyl) Amphotericin B To a stirred solution of amphotericin B (923 mg) in 10 ml dimethylsulfoxide and 1 ml of methanol under nitrogen is added 8.6 ml of a 0.21 M solution of the product of process step A in tetrahydrofuran. Sufficient dimethylsulfoxide is added to redissolve the precipitate fromed and the solution is stirred for 5 hours. Dilution with an equal volume of methanol and dropwise addition in 390 ml ether gives a yellow precipitate.. Filtration, washing with ether and drying gives the named compound: [&alpha;]26D+ 198.0 (DMSO) ; # max (KBr) 1720 cm-1. C. N-(L-Lysyl)Amphotericin B To N-(N',N"-Bis-Trichloroethoxycarbonyl-L-Lysyl) amphotericin B (1.04 g) in 40 ml of a 1:1 methanol:dimethylformamide mixture and (0.5 ml) acetic acid is added activated zinc dust (2.2 g). After 6.5 hours another 2.2 g zinc dust is added ,Afer 8 hours the mixture is decanted into 500 ml ether.; Filtration, washing with ether and drying gives a yellow powder. Chromatography on 135 g SiO2 eluted with the lower phase of a 1:1:1 chloroform:methanol:concentrated ammonium hydroxide mixture produces the named compound: # max (KBr) broad, 3600-2250 cm-1; 1690 cm-1 broad; # max (20% aqueous tetrahydrofuran), 348 nm (EÚ1%=230), 367 nm (EÚ1%=510), 386 nm (EÚ1%=860) and 410 nm (EÚ1%=930); [&alpha;]26D+225.9 (DMSO). D. N-L-Lysyl Amphotericin B Methyl Ester To N-L-lysyl amphotericin B (185 mg) in 10 ml of a 9:1 dimethylsulfoxide:methanol mixture is added excess etheral diazomethane. When a complete reaction is indicated by thin layer chromatography (SiO2, 1:1:1 chloroform: methanol:concentrated ammonium hydroxide), the mixture is treated with one drop of a 1:1 acetic acid:methanolsolution and diluted with 10 ml of methanol. The solution is added dropwise to excess ether which is filtered, collected, washed with ether and dried to yield the named compound: X max (20% aqueous tetrahydrofuran) 348 nm (E1%= 297), 367 nm (E1%= 646), 386 nm (E1%=1095), 410 nm (EÚ1%=1222). Example 5 N-D-Lysyl Amphotericin B Methyl Ester Dihydrochloride A. N,N'-Bis-(9-fluorenylmethyloxycarbonyl)-D-Lysine To a stirred solution of D-lysine hydrochloride (4.5g) in 175 ml of a sodium carbonate solution (10% in water): acetone (6:1) solution is added dropwise a solution of 9fluorenylmethyl azidoformate in acetone (150 ml). After 16 hours the mixture is diluted with water and washed three times with hexane. The mixture is then acidified with concentrated hydrochloric acid and extracted three times with ethyl acetate. The ethyl acetate solution is washed successively with dilute hydrochloric acid, water, saturated sodium bicarbonate solution, and brine, dried over magnesium sulfate, then concentrated in vacuo to about 20 ml. The solution is added to hexane (1 li) and the precipitate is collected and dried to afford the title compound: NMR (dimethylsulfoxide) 6 l,0-1.9(m,6H), 2.7-3.2 (m,2H), 3.8-4.7 (m,7H), 6.8-8.3 (m,19H). B. N N,N'-Bis-(9-Fluorenylmethyloxyearbonyl)-D-LysylOxy Succinimide To a stirred solution of N,N'-bis-(9-fluorenylmethyloxy- carbonyl)-D-lysine (12.0 g) in 360 ml of an ethylacetate: dimethylformamide (35:1) mixture are added N-hydroxysuccinimide (3.1 g), l-ethyl-3-(3-dimethylaminopropyl)- carbodiimide hydrochloride (5.2 g) and diisopropylethylamine (2.0 ml). After 15 hours the solution is washed successively with dilute hydrochloric acid, water, saturated sodium bicarbonate solution, and brine, dried over magnesium sulfate, and concentrated in vacuo to about 20 ml. The solution is added to hexane (1 li) and the precipitate is collected and dried to afford the title compound. C. N-[N',N"-Bis-(9-Fluorenylmethyloxycarbonyl)-D Lysyl] Amphotericin B To a solution of N,N'-bis(9-fluorenylmethy1oxycarbonyl)- D-lysyloxy succinimide (o.60 g) in 22 ml of a dimethyl formamide:dimethylsulfoxide:methanol (8:2:1) mixture is added amphotericin B (0.50 g). The solution is stirred at 40 for 2.5 hours, diluted with methanol (10 ml), and added to ether (500 ml). The yellow precipitate is filtered, washed with ether, and dried. Chromatography on SiO2 (30 g) eluted with the lower phase of a 2:2:1 chloroform:methanol:water mixture produces the named compound. D. N-[Ny'N"-Bis-(9-Pluorenylmethyloxyearbonyl)-D-LySyl] Amphotericin B Methyl Ester To a stirred solution of N-[N',N"-bis-(9-fluorenylmethyloxycarbonyl)-D-lysyl]amphotericin B (1.4 g) in 55 ml of a dimethylsulfoxide:methanol (10:1) mixture are added methyliodide (1.6 ml) and diisopropylethylamine (1.2 ml). After 1 hour the solution is diluted with methanol (25 ml) and added to ether (1.5 1). The yellow precipitate is filtered and washed successively with ether, water, methanol:water (1:1) mixture, ether, and then dried to provide the title compound. E. N-D-Lysyl Amphotericin B Methyl Ester Dihydrochloride To a stirred solution of N-[N',N-bis-(9-fluorenylmethyloxy- carbonyl)-D-lysyl] amphotericin B methyl ester (1.2 g) in 50 ml of a dimethylsulfoxide:methanol (10:1) mixture is added 1,5-diazabicyclo[5.4.0]undec-5-ene (0.35 ml). After 0.5 hour the solution is diluted with methanol (25 ml) - and added to ether (1 li). The yellow precipitate is filtered, washed with ether, and dried. The yellow powder is suspended in water (100 ml) and 1.0 n-hydrochloric acid is added until a pH of 5,5 is reached. The solution is filtered through a 0.22 micropore filter. The filtrate is lyophilized to afford the title compound: X max (20% aqueous tetrahydrofuran) 348 nm (EÚ1%=278), 367 nm (EÚ1%=608), 387 nm (EÚ1%=1023), 410 nm (EÚ1%=1146). Example 6 N-Glycyl Derivative of the Polyene Macrolide Antibiotic 67-121-C A. N-Iodoacetyl Derivative of the Polyene Macrolide Antibiotic 67-121-C 67-121-C (600 mg) is dissolved in 10 ml of a 9:1 dimethylsulfoxide:methanol mixture. This solution is chilled and to it iodoacetic anhydride (180 mg) is added. The reaction is stirred at--room temperature. Completion of the reaction is checked by thin layer chromatography (chloro- form-methanol-water 2:2:1 - lower phase). The resulting solution is diluted with an equal volume of methanol and added to vigorously stirred ether. The precipitate is filtered to yield the named compound. B. N-Glycyl Derivative of the Polyene Macrolide Antibiotic -6-7 -121-C The product of step A is dissolved in a solution of dimethylformdmide (10 ml) and concentrated ammonium hydroxide (28%; 3 ml). The reaction mixture is stirred for 2 hours and the volume is reduced to remove the aqueous ammonia. The residue is diluted with an equal volume of methanol and added to vigorously stirred ether. The precipitate is filtered and chromatcgraphed on a silica gel column (chloroform:methanol:water (2:2:1)-lower phase) to obtain the title compound: [&alpha;]26D+117 (dimethyl D sulfoxide) ; X max (20% aqueous tetrahydrofuran) 382 nm Ú1%=765), 405 (EÚ1 (E1%=765), 405 (E1%=660). Example 7 N-(ss-Aminoethylglycyl)Amphotericin B Methyl Ester To 30 ml of a 9:1 dimethylsulfoxide:methanol mixture and 2.46 ml of ethylenediamine is added N-iodoacetyl amphotericin B, which may be prepared in a manner similar to Example 6A, over 2.25 hours. The mixture is stirred 1.5 hours and then diluted with an equal volume of methanol. The solution is added to vigorously stirred 500 ml of ether. The precipitate is filtered and washed with ether to yield N-(ss-aminoethylglycyl)amphotericin B. In a manner similar to that described in former Examples this compound can be transformed to the corresponding methylester: max (KBr) 1715 cm 1; # max (20% aqueous tetrahydrofuran) 348 nm (EÚ1%=296), 367 nm (EÚ1%=639), 386 nm (EÚ1%=1074), 410 nm (EÚ1%=1167). Example 8 Amphotericin B Propargyl Ester Hydrochloride To a stirred solution of benzaldehyde (2.0 ml) in 22 ml of a 10:1 dimethylsulfoxide:methanol mixture is added amphotericin B -(0.50 g). After 1 hour, diisopropylethylamine (1.0 ml) and propargyl bromide (1.0 ml of an 80% solution in toluene) are added. After 2 hours, 10 ml of methanol are added and the solution is added to 500 ml of ether. The precipitate is collected and washed successively with ether, water, methanol:water (1:1), and ether. The dried powder is suspended in water (40 ml) and 0.01 Nhydrochloric acid is added to a pH of 5. The solution is filtered through a 0.22 micropore filter, and the filtrate is lyophilized to afford the title compound, X max (20% aqueous tetrahydrofuran) 348 nm (E1%=350), 367 nm (EÚ1%=764), 387 nm (EÚ1%=1290), 410 nm (EÚ1%=1438) I 387 nm¯¯E1--1290) 410 nm In a manner analog to those described above also other. compounds of this invention can be prepared e.g. by treating amphotericin B, ascocin, aureofacin, aureofungin A, aureofungin B, candicidin, candidin, eurotin A, flavomycin, fulvomicin A, fulvomicin B, fulvomicin C, fungimycin, hamycin A, leucensomycin, levorin, mycoheptin, nystatin A, partricin, pimaricin, polyfungin, rimocidin, trichomycin A, vacidin A, DJ-400 B1., DJ-400 B2, 67-121A, 67-121B, 67-121C, PA 150, PA 616, 2814 H with the apropriate derivative of the desired amino compound such as glycine, lysine, glycylglycine, ornithine and ethanolamine or by transforming said polyene macrolide antibiotics into their respective N-iodoacetyl derivatives and reacting these derivatives with the apropriate amino compound such as ammonia, ethylenediamine and methylamine to obtain the respective N-glycyl, N-ss-aminoethylglycyl or N-methylglycyl derivative of the relevant polyene macrolide antibiotic. Esters and acid addition salts of this invention are prepared according to known methods, especially according to the Examples. The following compounds have been prepared accordingly; N-D-lysyl-pimaricin methyl ester dihydrochloride, N-(2- aminoethoxycarbonyl)amphotericin B methyl ester; 26 a] D+2819 (dimethylsulfoxide); Amax (20 aqueous tetra- hydrofuran) 348 nm (E11=327), 367 nm (E11%=715), 386 nm (EÚ1%=1206), 410 nm (EÚ1%=1341), N-ss-alanyl amphotericin B methyl ester hydrochloride, N-L-histidyl amphotericin B methyl ester dihydrochloride, #max (20% aqueous tetrahydrofuran): 348 nm (EÚ1% =257), 367 nm (EÚ1% =556), 387 nm (EÚ1% =935), 410 nm (EÚ1% =1036), N-D-tryptophyl amphotericin B methyl ester hydrochloride, #may (20% aqueous tetrahydrofuran): 348 nm (EÚ1% =315), 367 nm (EÚ1% =693), 387 nm (EÚ1% =1145), 410 nm (EÚ1% =1230), N-D,L-2,3-diaminopropionyl amphotericin B methyl ester dihydrochloride, #max (20% aqueous tetrahydrofuran): 348 nm (EÚ1% =304), 367 nm (EÚ1% =668), 387 nm (EÚ1% =1128), 410 nm (EÚ1% =1264), N-D,L-2,4-diaminobutyryl amphotericin B methyl ester dihydrochloride, #max (20% aqueous tetrahydrofuran): 348 nm (EÚ1% =307), 367 nm (E1%=676), 387 nm (EÚ1% =1148), 410 nm (EÚ1% =1292), N-D-2,4-diaminobutyryl amphotericin B methyl ester, N-L-2,4-diaminobutyryl amphoteriein B methyl ester dihydrochloride, #max (20% aqueous tetrahydrofuran): 348 nm (EÚ1% =319), 367 nm (EÚ1% =702), 387 nm (EÚ1% =1188), 410 nm (EÚ1% =1340), N-D,L-2,4-diaminobutyryl amphotericin B propargyl ester dihydrochloride, #max (20% aqueous tetrahydrofuran): 348 nm (EÚ1% =294), 367 nm (EÚ1% =635), 387 nm (EÚ1% =1069), 410 nm (EÚ1% =1192), N-D,L-ornithyl amphotericin B hydrochloride, #max (20% aqueous tetranydro@uran) @00 nm (E1%=740), 386 nm (EÚ1% =1260), 400 nm (EÚ1% =1400), N-D,L-ornithyl amphotericin B methyl ester, Amax (20% aqueous tetrahydrofuran) 365 nm (E1=590), 386 nm (EÚ1% =990), 401 nm (EÚ1% =1100), N-L-ornithyl amphotericin B methyl ester dihydrochloride, #max 20% aqueous tetrahydrofuran): 348 nm (EÚ1% =300), 367 nm (EÚ1% =667), 387 nm (EÚ1% =1124), 410 nm (EÚ1% =1251), N-D-ornithyl amphotericin B methyl ester dihydrochloride, #max (20% aqueous tetrahydrofuran): 348 nm (EÚ1% =315), 367 nm (EÚ1% =692), 387 nm (EÚ1% =1171), 410 nm (EÚ1% =1312) N-D-ornithyl amphotericin B propargyl ester dihydrochloride. #max (20% aqueous tetrahydrofuran): 348 nm (EÚ1% =270), 367 nm (EÚ1% =574), 387 nm (EÚ1% =957), 410 nm (EÚ1% =1054), N-D-ornithyl amphotericin B (3-phenyl-2-propynyl) ester dihydrochloride, #max (20% aqueous tetrahydrofuran): 348 nm (EÚ1% =254), 367 nm (EÚ1% =540), 387 nm (EÚ1% =905), 410 nm (EÚ1% =986), N-D-ss-lysyl amphotericin B methyl ester dihydrochloride, #max (20% aqueous tetrahydrofuran): 348 nm (EÚ1%=291), 367 nm (EÚ1%=636), 387 nm (EÚ1%=1075), 410 nm (EÚ1%=1205), N-L-ss-lysyl amphotericin B methyl ester dihydrochloride, #max (20% aqueous tetrahydrofuran): 348 nm (EÚ1%=290), 367 nm (EÚ1%=640), 387 nm (EÚ1%=1080), 410 nm (EÚ1%=1205), N-glycylglycyl amphotericin B, #max (20% aqueous tetrahydrofuran) 367 nm (EÚ1%=760), 386 nm (EÚ1%=1280), 401 nm (EÚ1%=1430), N-glycylglycyl amphotericin B methyl ester, Xmax (20% aqueous tetrahydrofuran) 367 nm (EÚ1%=710), 386 nm (EÚ1%= 1200), 401 nm (EÚ1 p N-(N',N"-diglycyl-D-lysyl) amphotericin B methyl ester dihydrochloride, #max (20% aqueous tetrahydrofuran): 348 nm (EÚ1%=263), 367 nm (EÚ1%=578), 387 nm (EÚ1%=1012), 410 nm (EÚ1%=1094), N-D-lysyllysyl amphotericin B methyl ester amphotericin B allyl ester hydrochloride, #max (20% aqueous tetrahydrofuran): 348 nm 1 367 nm aqueou tetrahydrofuran): 348 nm (E1%=359), 367 nm (EÚ1%=797), 387 nm (EÚ1%=1352), 410 nm (EÚ1%=1518), amphotericin B-(3-phenyl-2-propynyl) ester hydrochloride, Amax (20% aqueous tetrahydrofuran): 348 nm (EÚ1%=269), 367 nm (EÚ1%=559), 387 nm (EÚ1%=919), 410 nm (EÚ1%=1011), N-D-2,4-diaminobutyryl amphotericin B methyl ester dihydrochloride [&alpha;]25D+256.6 (dimethylsulfoxide), N-D-2,4-diaminobutyryl amphotericin B propargyl ester dihydrochloride [&alpha;]25D+228.4 (dimethylsulfoxide). The following formulations exemplify the formulations in which the compounds of this invention can be used. The formulations are prepared by methods known in the art. FORMULATIONS Formulation 1 Cream mg/g N-glycyl amphotericin B methyl 50.0 ester hydrochloride white petrolatum 150.0 mineral oil 60.0 cetyl alcohol 36.0 stearyl alcohol 36.0 cetomacrogal 1000 22.0 4-chlor-m-cresol 1.0 purified water to make 1 g. Formulation 2 Ointment mg/g N-glycyl amphotericin B methyl 10.0 ester hydrochloride propylene glycol 100 propylene glycol monostearate 20.0 white wax 60.0 white petrolatum, sufficient 1 g. to make Formulation 3 Zdt ion mg/ml N-glycyl amphotericin B methyl 50.0 ester hydrochloride isopropyl myristate 20.0 glycerol stearate 2.0 promalgen 6 3.0 propylene glycol 15.0 purified water, sufficient 1 ml to make Formulation 4 Aqueous Suspension for Intramuscular of Subcutaneous Injection ve mg/ml N-glycyl amphotericin B methyl 70.0-100.1 ester polysorbate 80, USP 0.5 mg/ml benzyl alcohol 9.0 sodium chloride 5.0 methylparaben 1.3 propylparaben 0.2 sodium carboxymethylcellulose 5.0 disodium edetate 0.1 polyethylene glycol 20.0 water for injection, sufficient 1.0 ml. to make Formulation 5 Intravenous Injection (Supplied as Sterile Lyophilized Powder) mg/vial N-glycyl amphotericin B methyl 40.0-60.0 ester hydrochloride sodium desoxycholate 70.0 dibasic sodium phosphate (anhydrous) 16.0 monobasic sodium phosphate (anhydrous) 9.0 Formulation 6 Oral Suspension (to give a dose of 25 mg./5 ml.) N-glycyl amphotericin B methyl ester hydrochloride 5.00 g. Magnesium Aluminum Silicate 9.5 g. Sodium carboxymethylcellulose, U.S.P. 2.5 g. Sodium Citrate, U.S.P. 25.0 g. Flavor q.s. Color q.s. Methylparaben, U.S.P. 0.9 g. Propylparaben, U.S.P. 0.2 g. ; Polysorbate 80, U.S.P. 1.0 g. Sorbitol Solution, U.S.P. 500.0 g. Water q.s. 1000.0 z 0 g. Procedure: 1. Heat 200 ml.of water to boiling, and dissolve in it one half of the parabens. Cool to about 70 C, then mix in the Polysorbate 80. Sprinkle in the silicate, stirring until a uniform smooth suspension results. 2. Heat an additional 200 ml. of water to boiling, and dissolve in it the remainder of the parabens. Disperse the carboxymethylcellulose in this until a smooth gel results. Mix in the Sorbitol Solution. Then introduce and dissolve the sodium citrate. 3. Add 2 to 1 slowly, with constant stirring. Cool the mixture to 25 C. Add the N-glycyl amphotericin B methyl ester hydro chloride, flavor and color, mixing thoroughly. Add sufficient quantity of water to make the total volume 1000 ml. Claims for designated countries other than Austria. 1. Polyene macrolide antibiotic derivatives of the general formula EMI43.1 wherein M is a polyene macrolide antibiotic moiety containing an amino sugar moiety, the amino group of which is substituted by X, wherein X is EMI43.2 -R5 or hydrogen, wherein A and B independently of each other are hydrogen or NR4R4 or one of A and B is hydrogen and the other is O -NH-C-R-NR3R4; R is a saturated hydrocarbon group having 3 1 to 10 carbon atoms; R1 and R2 independently of each other are hydrogen or a straight chain alkyl group having 1 to 3 carbon atoms or one of R1 and R2 is hydrogen and the other a straight chain alkyl group having 1 to 3 carbon atoms substituted by an NH2 group; R3 and R4 independently of each other are hydrogen or a straight chain alkyl group containing 1 to 3 carbon atoms; R5 is histidyl, tyrosyl, tryptophyl, arginyl, phenylalanyl or prolyl or an (a)-N-[(NH2)&num; R+CO ]- derivative of histidyl, tyrosyl, tryptophyl, phenylalanyl or prolyl; m is 1 or 2; n is 1 to 3, t is zero or 1, and when t is zero p is zero to 4 and when t is 1 p is zero; with the proviso that not more than one hetero atom is attached to the same carbon atom in any one of R, R1 and R2 and that in those compounds containing more than one R-group, these R-groups may be of the same or different chain length; z is zero or 1, and Y is hydrogen, an alkyl group containing 1 to 10 carbon atom allyl, propargyl, benzyl or phenylprppargyl, with the proviso that, when X is hydrogen, z must be 1 and Y allyl, propargyl, benzyl or phenylpropargyl; and the pharmaceutically acceptable acid addition salts of all the foregoing compounds. 2. A compound according to claim 1 which is derived from a polyene macrolide antibiotic of the general formula EMI44.1 wherein z is zero or 1, which nolxyene macrolide antibiotic is amphotericin B, ascocin, aureofacin, aureofungin A, aureofungin B, candicidin, candidin, eurotin A, flavomycin, fulvomicin A, fulvomicin B, fulvomicin C, fungimycin, hamycin A, leucensomycin, levorin, mycoheptin, nystatin A, partricin, pimaricin, polyfungin, rimocidin, trichomycin A, vacidin A, DJ-400 B1, DJ-400 B2, 67-121A, 67-121B, 67-121C, PA 150, PA 616, or 2814 H, preferably from amphotericin B, pimaricin or 67-121C. 3. A compound according to claim 1 or 2, wherein X is EMI45.1 wherein n is 1 or 2 and R, R1 and R2 are as defined in claim 1. 4. A compound according to any one of claims 1 to 3 wherein R is a saturated hydrocarbon group having 1 to 5 carbon atoms and R1, R2, R3 and R4 are hydrogen. 5. A compound according to any one of claims 1 wherein z is 1 and Y is methyl. 6. A compound according to claim 1 or 2 wherein hydrogen, z is one and Y is allyl; propargyl or phenylpropargyl. 7. A compound according to claim 1 which is N-Dlysyl amphotericin B methyl ester, N-D-ornithyl ampho tericin B methyl ester, N-D-lysyl pimaricin methyl ester, N-glycyl 67-121C, N-glycyl amphotericin B methyl ester, N-D-2,4-diaminobutyryl amphotericin B methyl ester, N-8-alanyl amphotericin B methyl ester, N-.(aminoethylglycyl) amphotericin B, N-(aminoethylglycyl) amphotericin B methyl ester, .N-D-lysyl amphotericin B, N-L-lysyl amphotericin B, N-L-lysyl amphotericin B methyl ester, N-Lornithyl amphotericin B methyl ester, N-D-ornithyl amphotericin B propargyl ester, N-(2-aminoethoxycarbonyl) amphotericin B methyl ester, N-L-histidyl amphotericin B methyl ester, amphotericin B aIlyl ester, amphotericin B propargyl ester, or amphotericin B (3-phenyl-2-propynyl) ester, or a pharmaceutically acceptable acid addition salt, especially the hydrochloride salt, thereof. 8. Process for the preparation of a polyene macrolide antibiotic derivative of the general formula EMI46.1 wherein M, X and z are as defined in claim 1, and Y is hydrogen, an alkyl group conainining 1 to 10 carbon atoms, allyl, propargyl, benzyl or phenylpropargyl, with the proviso that, when X is hydrogen z must be 1 and Y must be an alkyl group containing 1 to 10 carbon atoms, allyl, propargyl, benzyl or phenylpropargyl; or a pharmaceutivally acceptable acid addition salt thereof, characterized in that one of the following processes is applied: a) fo@ the preparation of a compound of the general formula I, defined as in claim 1: reaction of a polyene macrolide antibiotic of the general formula EMI47.1 wherein M, Y and z are as defined in claim 1, is reacted with a reactive derivative of a compound of the general formula HOX(VII), wherein X' is defined as group X in claim 1 wit1: :' the exception that any free amino group contained therein is protected, followed by the rem@al of the protecting group(s) and/or esterificaton of compounds containing a carboxyl group; b) for the preparation of a derivative of a polyene macrolide antibiotic of the general formula EMI48.1 wherein M is a polyene macrolide antibiotic moiety containing an amino sugar moiety, the amino group of which is substituted by X, wherein X is -CO-CH2-NHB1 (X), wherein R1 is hydrogen, or a straight chain alkyl group having 1 to 3 carbon atoms which may be substituted by an NH2 group; z is zero or 1, and Y is hydrogen, an alkyl group containing 1 to 10 carbon atoms, allyl, propargyl, benzyl or phenylpropargyl, with the proviso that, when X is hydrogen, z must be 1 and Y allyl, propargyl, benzyl or phenylpropargyl: reaction of a N-iodoacetyl derivative of the polyene macrolide antibiotic with an amine of the general formula H2NR1 (XI), wherein R1 is as defined above and, followed if desired, by esterification where the macrolide contains a carboxyl group; c) for the preparation of a derivative of a polyene macrolide antibiotic of the general formula EMI49.1 wherein M is as defined above, X is hydrogen, z is one and Y is an alkyl group containing 1 to 10 carbon atoms, allyl, propargyl, benzyl or phenylpropargyl: reaction of a carboxylic acid salt of an appropriate polyene macrolide antibiotic which contains a carboxyl group and wherein the amino group of the amino sugar moiety has been protected by the treatment with an excess of an aromatic aldehyde, is reacted with the reactive derivative of the relevant alkane, propene, propyne, phenylpropyne or toluene, followed by deprotection of the amino group and isolation of the desired product; and if desired the so obtained product is tra,$,formed into a pharmaceutically acceptable acid addho salt. 9. A compound of the general formula (I) as defined in any one of claims 1 to 7 or obtained by a process of claim 8 for use in treating fungal infections. 10. A pharmaceutical composition comprising as active ingredient at least one compound of the general formula (I) as defined in any one of claims 1 tO 7 or obtained by a process of claim 8 together with a pharmaceutically acceptable carrier.

Claims: Claims for Austri-a 1. Process for the preparation of polyene macrolide antibiotic derivatives of the general formula EMI51.1 wherein M is a polyene macrolide antibiotic moiety containing an amino sugar moiety, the amino group of which is substituted by X, wherein X is EMI51.2 wherein A and B independently of each other are hydrogen or NR3R4 or one of A and B is hydrogen and the other is EMI51.3 R is a saturated hydrocarbon group having 1 to 10 carbon atoms; R1 and R2 independently of each other are hydrogen or a straight chain alkyl group having 1 to 3 carbon atoms or one of R1 and R2 is hydrogen and the other a straight chain alkyl group having 1 to 3 carbon atoms substituted by an -NH2 group; R3 and R4 independently of each other are hydrogen or a straight chain alkyl group containing 1 to 3 carbon atoms; R5 is histidyl, tyrosyl, tryptophyl, arginyl, phenylalanyl or propyl or an (a)-N-[(NH2)m EMI52.1 CO ]- derivative of histidyl, tyrosyl, tryptophyl, phenylalanyl or prolyl; m is I or 2; n is 1 to 3, t is zero or 1, and when t is zero p is zero to 4 and when t is 1 p is zero; with the proviso that not more than one hetero atom is attached to the same carbon atom in any one of R, R1 and R2 and that in those compounds containing more than one R-group, these R-groups may be of the same or different chain length; z is zero or 1, and Y is hydrogen, an alkyl group containing 1 to 10 carbon atoms, allyl, propargyl, benzyl or phenylpropargyl, with the proviso that, when'X is hydrogen, z must be 1 and Y mu,st be an alkyl group containing 1 to 10 carbon atoms, allyl, propargyl, benzyl or phenylpropargyl; and the :pharmaceutically acceptable acid addition salts of all the foregoing compounds, characterized in that one of the following processes is applied: a) for the preparation of a compound of the general formula (I), wherein M is a polyene macrolide antibiotic moiety containing an amino sugar moiety, the amino group of which is substituted by X, wherein X is EMI53.1 -R5 wherein A and B independently of each other are hydrogently of each other are hydrogen or NR3R4 or one of A and B is hydrogen and the other is hydrogen and the other is EMI53.2 R is a saturated hydrocarbon group having 1 to 10 carbon atoms; Bl and R2 independently of each other are hydrogen or a straight chain alkyl group having 1 to 3 carbon atoms or one of B1 and R2 is hydrogen and the other a straight chain alkyl group having 1 to 3 carbon atoms substituted by an NH2 group; ; R3 and R4 independently of each other are hydrogen or a straight chain alkyl group containing 1 to 3 carbon atoms; R5 is histidyl, tyrosyl, tryptophyl, arginyl, phenylalanyl or prolyl or an (a)-N EMI53.3 - derivative of histidyl, tyrosyl, tryptophyl, phenylalanyl or prolyl; m is 1 or 2; n is 1 to 3, t is zero or 1, and when t is zero P is zero to 4 and when t is 1 p is zero; with the proviso that not more than one hetero atom is attached to the same carbon atom in any one of R, R1 and R2 and that in those compounds containing more than one B-group, these R-groups may be of the same or different chain length; z is zero or 1, and Y is hydrogen, an alkyl group containing 1 to 10 carbon atoms, allyl, propargyl, benzyl or phenylpropargyl: reaction of a polyene macrolide antibiotic of the general formula EMI54.1 wherein M, Y and z are as defined above, is reacted with a reactive derivative of a compound of the general formula HOX' (VII), wherein X' is defined as group X above with the exception that any free amino group contained therein is protected, followed by the removal of the protecting - group(s) and/or esterification of compounds carboxy 1 carboxyl group; is r b) for the preparation of a compound of the general formula (I), wherein M is a polyene macrolide antibiotic moiety containing an amino sugar moiety, the amino group of which is substituted by X, wherein X is -CO-CH2-NHR1 (X), wherein R1 is hydrogen, or a straight chain alkyl group having 1 to 3 carbon atoms which may be substituted by an NH2 group; z is zero or 1, and Y is hydrogen, an alkyl group containing 1 to 10 carbon atoms, allyl, propargyl, benzyl or phenylpropargyl: reaction of a N-iodoacetyl derivative of the polyene macrolide antibiotic with an amine of the general formula H2NR1. (XI), wherein R1 is as defined above and, followed if desired, by esterification provided the macrolide contains a carboxyl group; c) for the preparation of a compound of the general formula (I), wherein M is as defined above and X is hydrogen, z is one and Y is an alkyl group containing 1 to 10 carbon atoms, allyl,propargyl, benzyl or phenylpropargyl; reaction of a carboxylic acid salt of an appropriate polyene macrolide antibiotic which contains a carboxyl group and wherein the amino group of the amino sugar moiety has been protected by the treatment with an excess of an aromatic aldehyde, is reacted with the reactive derivative of the relevant alkane, propene, propyne, phenylpropyne or toluene, followed by deprotection of the,amino group and isolation of the desired product; and if desired the so obtained product is transformed into a pharmaceutically acceptable acid addition salt. 4 2. Process according to claim 1 characterized in that the polyene antibiotic starting. material is selected from amphotericin B, ascocin, aureofacin, aureofungin A, aureofungin B, candicidin, candidin, eurotin A, flavomycin, fulvomicin A, fulvomicin B, fulvomicin C, fungimycin, hamycin A, leucensomycin, levorin, mycoheptin, nystatin A, partricin, pimaricin, polyfungin, rimocidin, trichomycin A, vacidin A, DJ-400 B1, DJ-400 B2, 67-121A, 67-121B, 67-121C, PA 150, PA 616 and 2814 H, preferably from amphotericin B, pimaricin and 67-121C. Process according to claim la or 2 characteri zed in that for the preparation of compounds of formula wherein z is one and Y is an alkyl group containing 1 to 10 carbon atoms, allyl, propargyl, benzyl or phenyl propargyl, a polyene macrolide antibiotic of formula VI, wherein IT is as defined in claim 1, Y is hydrogen and z is one,, is reacted with a compound ZX'; wherein X' is as defined in claim"1, the amino group(s) being protected by fluorenemethoxycarbonyl group(s), and Z is N-hydroxysuccinimidyl, which reaction is followed by esterification and then by removal of the protecting group(s). 4. Process- according to any one of claims 1 to 3, characterized in that a compound of formula I is prepared wherein X is EMI57.1 wherein n is 1 or 2 and R, R1 and R2 are as defined in claim 1, R preferably being a saturated hydrocarbon group having 1 to 5 carbon atoms. 5. Process according to any one of claims 1 to 4 characterized in that a compound of formula I is prepared wherein R1, R2, R3 and R4 are hydrogen. 3 6. Process according to any one of claims 1 to 5, characterized in that a compound of formula I is prepared wherein X is lysyl, ornithyl, histidyl or tryptophyl. 7. Process according to any one of claims 1 to 6, characterized in that a compound of formula I is prepared wherein Z is 1 and Y is an alkyl group containing 1 to 4 carbon atoms, preferably being methyl. 8. Process according to any one of claims 1 to 3, characterized in that a compound of formula I is prepared wherein X is hydrogen, z is one and Y is allyl, propargyl or phenylpropargyl. 9. Process according to claim 1, characterized in that a compound of formula I is prepared which is N-Dlysyl amphotericin B methyl ester, N-D-ornithyl amphotericin B methyl ester, N-D-lysyl pimaricin methyl ester, N-glycyl 67-121C, N-glycyl amphotericin B methyl ester, -D-2,4-diaminobutyryl amphotericin B methyl ester, N-B-alanyl amphotericin B methyl ester, N-(aminoethylglycyl) amphotericin B, N-(aminoethylglycyl) amphotericin B methyl ester, N-D-lysyl amphotericin B, N-L-lysyl amphotericin B, N-L-lysyl amphotericin B methyl ester, N-Lornithyl amphotericin B methyl ester, N-D-ornithyl amphotericin B propargyl ester, N-(2-aminoethoxycarbonyl) amphotericin B methyl ester, N-L-histidyl amphotericin B methyl ester, amphotericin B allyl ester, amphotericin B propargyl ester, or amphotericin B (3-phenyl-2-propynyl) ester, or a pharmaceutically acceptable acid addition salt, especially the hydrochloride salt, thereof. 10. Process for the preparation of a pharmaceutical composition comprising as active ingredient at least one compound of the general formula (I) as defined in any one of claims 1 to 9 together with a pharmaceutically acceptable carrier.

Inventors: WRIGHT, JOHN JESSEN
Applicants: SCHERING CORPORATION
Application year: 1979
Main classification: C07H17
IPC codes: A61P31, A61K31, C07H17